<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593902</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD.CAST.2018</org_study_id>
    <nct_id>NCT03593902</nct_id>
  </id_info>
  <brief_title>Cardiac Safe Transplants for Systemic Sclerosis</brief_title>
  <acronym>CAST</acronym>
  <official_title>Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous&#xD;
      stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is&#xD;
      less toxic to your heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The autologous hematopoietic stem cell transplant used in this research study is an&#xD;
      investigational procedure that uses cyclophosphamide and fludarabine (chemotherapy), rabbit&#xD;
      anti-thymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be&#xD;
      causing your disease), and rituximab (a biologic drug that targets B cells of your immune&#xD;
      system). After use of these treatments, the patient will receive their own previously&#xD;
      collected blood stem cells (autologous stem cell transplant). The ability of these&#xD;
      experimental treatments to stop relapses and progression (worsening) of your systemic&#xD;
      sclerosis will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI Sabbatical&#xD;
  </why_stopped>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Skin Score by mRSS</measure>
    <time_frame>Pre Treatment and Post Treatment</time_frame>
    <description>Defined by at least a 25% improvement (decline) in skin score by modified Rodnan skin score (mRSS) if skin score is greater than 14 on enrollment. If skin score is less than 14 on enrollment, improvement is defined by at least a 5% improvement on mRSS. The modified Rodnan skin score (MRSS) is a measure for skin disease in scleroderma and is calculated by summation of skin thickness in 17 different body sites. The scale ranges from at total score of normal skin thickness (0) to severe thickness (51).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of Treatment</measure>
    <time_frame>During Treatment and Post Treatment up to 1 year</time_frame>
    <description>Survival of Hematopoietic Stem Cell Transplant during treatment and post treatment up to 1 year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>A chemotherapy medication commonly used in the treatment of leukemia and lymphoma</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>A medication used as chemotherapy and to suppress the immune system</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rATG</intervention_name>
    <description>A rabbit polyclonal antibody to lymphocytes</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>Anti-Thymocyte Globulin (Rabbit)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Solu-Medrol</other_name>
    <other_name>Depo-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IVIg</intervention_name>
    <description>Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Bivagam</other_name>
    <other_name>Carimune NF</other_name>
    <other_name>Gammagard</other_name>
    <other_name>Privigen</other_name>
    <other_name>Octagam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cells</intervention_name>
    <description>Infusion of patient's own stem cells</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 65 years old at the time of pre-transplant evaluation&#xD;
&#xD;
          2. An established diagnosis of systemic sclerosis&#xD;
&#xD;
          3. Diffuse cutaneous systemic sclerosis with involvement proximal to the elbow or knee&#xD;
             and a modified Rodnan Skin Score of â‰¥ 14 (see Appendix A)&#xD;
&#xD;
        AND&#xD;
&#xD;
        Any one of the following:&#xD;
&#xD;
          1. DLCO &lt; 80% of predicted or decrease in lung function (DLCO, DLCO/VA or FVC) of 10% or&#xD;
             more over 12 months.&#xD;
&#xD;
          2. Pulmonary fibrosis or alveolitis on CT scan or chest x-ray (ground glass appearance of&#xD;
             alveolitis).&#xD;
&#xD;
          3. Abnormal EKG (non-specific ST-T wave abnormalities, low QRS voltage, or ventricular&#xD;
             hypertrophy), or pericardial effusion or pericardial enhancement without constriction&#xD;
             on MRI&#xD;
&#xD;
          4. Gastrointestinal tract involvement confirmed on radiological study. Radiologic&#xD;
             findings of scleroderma are small bowel radiographs showing thickened folds with&#xD;
             dilated loops, segmentation, and flocculation +/- diverticula, or pseudodiverticula. A&#xD;
             hide-bound appearance may be present (e.g. dilated and crowded circular folds). GI&#xD;
             involvement may also be confirmed by D-xylose malabsorption, patulous esophagus on&#xD;
             high-resolution computed tomography (HRCT), or esophageal manometry.&#xD;
&#xD;
        OR&#xD;
&#xD;
        Limited cutaneous systemic sclerosis (SSc) (modified Rodnan Skin Score &lt;14) with lung&#xD;
        involvement defined as active alveolitis on bronchoalveolar lavage (BAL), ground-glass&#xD;
        opacity on CT scan, a DLCO &lt; 80% predicted, or decrease in lung function (DLCO/VA, DLCO,&#xD;
        FVC) of 10% or more in last 12 months.&#xD;
&#xD;
        Other Inclusion Criteria for &quot;CAST&quot; Conditioning Regimen (presence of any of the&#xD;
        following):&#xD;
&#xD;
          1. Septal flattening or D-sign on MRI (without deep breathing)&#xD;
&#xD;
          2. PASP &gt;40 mm Hg or &gt;45 mm Hg with fluid challenge*&#xD;
&#xD;
          3. mPAP &gt;25 mm Hg or &gt;30 mm Hg with fluid challenge*&#xD;
&#xD;
          4. Non-ischemia diffuse ventricular hypokinesis or non-ischemia wall hypokinesis&#xD;
&#xD;
               -  Fluid challenge is 1000 ml normal saline over 10 minutes. Fluid challenge will&#xD;
                  not be done if right atrial pressure is &gt;13 mm Hg at rest or pulmonary capillary&#xD;
                  wedge pressure is &gt;20 mm Hg at rest.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active ischemic heart disease or untreated coronary artery disease&#xD;
&#xD;
          2. Untreated life-threatening cardiac arrhythmia on EKG or 24-hour holter&#xD;
&#xD;
          3. Pericardial effusion &gt; 1 cm on cardiac MRI unless successful pericardiocentesis has&#xD;
             been performed&#xD;
&#xD;
          4. LVEF &lt;35%&#xD;
&#xD;
          5. End-stage lung disease characterized by TLC&lt;45% of predicted value, or DLCO hemoglobin&#xD;
             corrected &lt; 30 % predicted.&#xD;
&#xD;
          6. Creatinine clearance &lt;40 by 24-hour urine&#xD;
&#xD;
          7. History of breast implants that have not been removed (unless they cannot be&#xD;
             surgically removed due to risks of surgery)&#xD;
&#xD;
          8. Liver cirrhosis, transaminases &gt;2x of normal limits, or bilirubin &gt; 2.0 unless due to&#xD;
             Gilbert's disease&#xD;
&#xD;
          9. Uncontrolled diabetes mellitus or any other illness that in the opinion of the&#xD;
             investigators would jeopardize the ability of the patient to tolerate aggressive&#xD;
             treatment&#xD;
&#xD;
         10. Prior history of malignancy&#xD;
&#xD;
         11. Positive pregnancy test, inability or unable to pursue effective means of birth&#xD;
             control, or failure to willingly accept or comprehend irreversible sterility as a side&#xD;
             effect of therapy&#xD;
&#xD;
         12. Psychiatric illness or mental deficiency making compliance with treatment or informed&#xD;
             consent impossible&#xD;
&#xD;
         13. Major hematological abnormalities such as platelet count &lt; 100,000/ul or absolute&#xD;
             neutrophil count (ANC) &lt; 1000/ul&#xD;
&#xD;
         14. HIV positive&#xD;
&#xD;
         15. Hepatitis B or C positive&#xD;
&#xD;
         16. PASP &gt;50 mmHg without fluid challenge&#xD;
&#xD;
         17. mPAP &gt;34 mmHg without fluid challenge&#xD;
&#xD;
         18. Coronary artery disease not reversed by cardiology and interventional radiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <results_first_submitted>July 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03593902/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03593902/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.&#xD;
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer&#xD;
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma&#xD;
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system&#xD;
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder&#xD;
rATG: A rabbit polyclonal antibody to lymphocytes&#xD;
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation&#xD;
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.&#xD;
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer&#xD;
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma&#xD;
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system&#xD;
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder&#xD;
rATG: A rabbit polyclonal antibody to lymphocytes&#xD;
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation&#xD;
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Rodnan skin score</title>
          <description>The modified Rodnan skin score (MRSS) is a measure for skin disease in systemic scleroderma and is calculated by summation of skin thickness in 17 different body sites. The range is 0 (normal skin thickness to 51 (severe thickness).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="0" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Skin Score by mRSS</title>
        <description>Defined by at least a 25% improvement (decline) in skin score by modified Rodnan skin score (mRSS) if skin score is greater than 14 on enrollment. If skin score is less than 14 on enrollment, improvement is defined by at least a 5% improvement on mRSS. The modified Rodnan skin score (MRSS) is a measure for skin disease in scleroderma and is calculated by summation of skin thickness in 17 different body sites. The scale ranges from at total score of normal skin thickness (0) to severe thickness (51).</description>
        <time_frame>Pre Treatment and Post Treatment</time_frame>
        <population>The number analyzed in one or more rows differs from the overall number analyzed because some patients did not follow up after the treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.&#xD;
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer&#xD;
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma&#xD;
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system&#xD;
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder&#xD;
rATG: A rabbit polyclonal antibody to lymphocytes&#xD;
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation&#xD;
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skin Score by mRSS</title>
          <description>Defined by at least a 25% improvement (decline) in skin score by modified Rodnan skin score (mRSS) if skin score is greater than 14 on enrollment. If skin score is less than 14 on enrollment, improvement is defined by at least a 5% improvement on mRSS. The modified Rodnan skin score (MRSS) is a measure for skin disease in scleroderma and is calculated by summation of skin thickness in 17 different body sites. The scale ranges from at total score of normal skin thickness (0) to severe thickness (51).</description>
          <population>The number analyzed in one or more rows differs from the overall number analyzed because some patients did not follow up after the treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="4" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="2" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival of Treatment</title>
        <description>Survival of Hematopoietic Stem Cell Transplant during treatment and post treatment up to 1 year.</description>
        <time_frame>During Treatment and Post Treatment up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.&#xD;
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer&#xD;
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma&#xD;
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system&#xD;
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder&#xD;
rATG: A rabbit polyclonal antibody to lymphocytes&#xD;
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation&#xD;
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and</description>
          </group>
        </group_list>
        <measure>
          <title>Survival of Treatment</title>
          <description>Survival of Hematopoietic Stem Cell Transplant during treatment and post treatment up to 1 year.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During Treatment and the First 100 days Post Treatment</time_frame>
      <desc>Grade 4 Toxicities</desc>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.&#xD;
Rituximab: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer&#xD;
Fludarabine: A chemotherapy medication commonly used in the treatment of leukemia &amp; lymphoma&#xD;
Cyclophosphamide: A medication used as chemotherapy and to suppress the immune system&#xD;
Mesna: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder&#xD;
rATG: A rabbit polyclonal antibody to lymphocytes&#xD;
Methylprednisolone: A corticosteroid medication used to suppress the immune system and decrease inflammation&#xD;
G-CSF: A glycoprotein that stimulates the bone marrow to produce granulocytes and</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of study due to PI Sabbatical led to small number of participants analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>kathleen.quigley@nm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

